"Psoriasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Descriptor ID |
D011565
|
| MeSH Number(s) |
C17.800.859.675
|
| Concept/Terms |
Pustulosis of Palms and Soles- Pustulosis of Palms and Soles
- Pustulosis Palmaris et Plantaris
- Palmoplantaris Pustulosis
- Pustular Psoriasis of Palms and Soles
|
Below are MeSH descriptors whose meaning is more general than "Psoriasis".
Below are MeSH descriptors whose meaning is more specific than "Psoriasis".
This graph shows the total number of publications written about "Psoriasis" by people in this website by year, and whether "Psoriasis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 3 | 4 |
| 1999 | 3 | 0 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 8 | 0 | 8 |
| 2004 | 4 | 0 | 4 |
| 2005 | 9 | 0 | 9 |
| 2006 | 9 | 0 | 9 |
| 2007 | 9 | 0 | 9 |
| 2008 | 10 | 1 | 11 |
| 2009 | 7 | 1 | 8 |
| 2010 | 8 | 1 | 9 |
| 2011 | 8 | 1 | 9 |
| 2012 | 6 | 2 | 8 |
| 2013 | 8 | 1 | 9 |
| 2014 | 8 | 0 | 8 |
| 2015 | 5 | 1 | 6 |
| 2016 | 12 | 1 | 13 |
| 2017 | 14 | 0 | 14 |
| 2018 | 24 | 1 | 25 |
| 2019 | 14 | 0 | 14 |
| 2020 | 14 | 1 | 15 |
| 2021 | 8 | 0 | 8 |
| 2022 | 7 | 0 | 7 |
| 2023 | 7 | 0 | 7 |
| 2024 | 7 | 1 | 8 |
| 2025 | 6 | 0 | 6 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Psoriasis" by people in Profiles.
-
AI-guided CRISPR screening reveals therapeutic targets in psoriasis. Nat Commun. 2026 Jul 06; 17(1).
-
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol. 2026 07 01; 162(7):709-719.
-
Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis. PLoS One. 2026; 21(1):e0341049.
-
SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. Br J Dermatol. 2026 01 06; 194(1):25-36.
-
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies. Am J Clin Dermatol. 2025 Nov; 26(6):967-979.
-
Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2025 12; 77(12):1487-1492.
-
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest. 2025 09 02; 135(17).
-
Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease: Current State. Rheum Dis Clin North Am. 2025 08; 51(3):537-544.
-
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025 09; 93(3):644-653.
-
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study. J Am Acad Dermatol. 2025 06; 92(6):1235-1242.